Fore Research & Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Fore Research & Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-10,000	Closed	-$1.25M	–	63
2015 Q1	$1.25M	Sell	10,000 -10,000	-50%	-$1.06M	0.05%	27
2014 Q4	$1.81M	Sell	20,000 -30,000	-60%	-$2.49M	0.1%	29
2014 Q3	$3.61M	Hold	50,000	–	–	0.11%	33
2014 Q2	$3.11M	Buy	50,000 +40,000	+400%	+$2.42M	0.09%	48
2014 Q1	$682K	Buy	+10,000	New	+$737K	0.02%	85

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Fore Research & Management's BMRN Position: Q2 2015 in Review

Fore Research & Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2015, closing a stake of 10,000 shares — an estimated $1.25M sold.

Fore Research & Management first reported a position in BMRN in Q1 2014 and held it in 5 quarters. The position peaked at $3.61M in Q3 2014. 391 funds tracked by Wall St. Rank hold BMRN as of Q2 2015.

Fore Research & Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
Fore Research & Management sold 10,000 BioMarin Pharmaceuticals shares in Q2 2015, an estimated $1.25M.
Fore Research & Management first reported a position in BioMarin Pharmaceuticals in Q1 2014 and held it in 5 quarters.
Fore Research & Management's BioMarin Pharmaceuticals position peaked at $3.61M in Q3 2014.
391 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2015.

Based on Fore Research & Management's 13F filing for Q2 2015, filed 14 Aug 2015.